FDA Wants Advisory Panel To Vote On Sarepta Muscle Wasting Drug Eteplirsen

FDA staff wants the advisory panel to vote on Sarepta's eteplirsen wasting drug after reviewing its effectiveness. An advisory panel meeting will include the recommendations of the FDA.